Fecal lactoferrin as a noninvasive biomarker in inflammatory bowel diseases

Drugs of Today

Volumn 48, Issue 2, 2012, Pages 149-161

  Langhorst, Jost ^a   Boone, J ^b  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b Research and Development   (United States)

Author keywords

Crohn's disease; Fecal biomarkers; Inflammatory bowel disease; Lactoferrin; Ulcerative colitis

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CALGRANULIN; INFLIXIMAB; LACTOFERRIN;

CAPSULE ENDOSCOPY; COLON CANCER; COLON POLYP; COLONOSCOPY; CROHN DISEASE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE ACTIVITY; DISEASE SEVERITY; ENDOSCOPY; ENTERITIS; FECES ANALYSIS; HISTOPATHOLOGY; HUMAN; ILEITIS; INTERMETHOD COMPARISON; IRRITABLE COLON; REMISSION; REVIEW; SENSITIVITY AND SPECIFICITY; SIGMOIDOSCOPY; TREATMENT RESPONSE; ULCERATIVE COLITIS;

BIOLOGICAL MARKERS; ENDOSCOPY, GASTROINTESTINAL; FECES; HUMANS; INFLAMMATORY BOWEL DISEASES; LACTOFERRIN; LEUKOCYTE L1 ANTIGEN COMPLEX;

EID: 84858249372     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2012.48.2.1732555     Document Type: Review

References (62)

1. Langhorst, J., Elsenbruch, S., Koelzer, J., Rueffer, A., Michalsen, A., Dobos, G. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel disease: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical Indices. Am J Gastroenterol 2008, 103(1): 162-9.
2. Vermeire, S., Van Assche, G., Rutgeerts, P. Laboratory markers in IBD: Useful, magic, or unnecessary toys? Gut 2006, 55(3): 426-31. (Pubitemid 43268284)
3. Mazlam, M.Z., Hodgson, H.J. Peripheral blood monocyte cytokine production and acute phase response in inflammatory bowel disease. Gut 1992, 33(6): 773-8.
4. Niederau, C., Backmerhoff, F., Schumacher, B., Niederau, C. Inflammatory mediators and acute phase proteins in patients with Crohn's disease and ulcerative colitis. Hepatogastroenterology 1997, 44(13): 90-107. (Pubitemid 27096020)
5. de Vries, M., van der Horst-Bruinsma, I., van Bodegraven, A., von Blomberg, B., Ratnawati, H., Dijkmans, B. pANCA, ASCA, and OmpC antibodies in patients with ankylosing spondylitis without inflammatory bowel disease. J Rheumatol 2010, 37(11): 2340-4.
6. Zholudev, A., Zurakowski, D., Young, W., Leichtner, A., Bousvaros, A. Serologic testing with ANCA, ASCA, and anti- OmpC in children and young adults with Crohn's disease and ulcerative colitis: diagnostic value and correlation with disease phenotype. Am J Gastroenterol 2004, 99(11): 2235-41. (Pubitemid 39524716)
7. Markowitz, J., Kugathasan, S., Dubinsky, M. et al. Age of diagnosis influences serologic responses in children with Crohn's disease: a possible clue to etiology? Inflamm Bowel Dis 2009, 15(5): 714-9.
8. Papp, M., Altorjay, I., Dotan, N. et al. New serological markers for inflammatory bowel disease are associated with earlier age at onset, complicated disease behavior, risk for surgery, and NOD2/CARD15 genotype in a Hungarian IBD cohort. Am J Gastroenterol 2008, 103(3): 665-81. (Pubitemid 351405992)
9. Bitton, A., Peppercorn, M., Antonioli, D. et al. Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis. Gastroenterology 2001, 120(1): 13-20. (Pubitemid 32061864)
10. Linskens, R., van Bodegraven, A., Schoorl, M. et al. Predictive value of inflammatory and coagulation parameters in the course of severe ulcerative colitis. Dig Dis Sci 2001, 46(3): 644-8. (Pubitemid 32299823)
11. Moran, A., Jones, A., Asquith, P. Laboratory markers of colonoscopic activity in ulcerative colitis and Crohn's colitis. Scand J Gastroenterol 1995, 30(4): 356-60.
12. Schunk, K., Kern, A., Oberholzer, K. et al. Hydo-MRI in Crohn's disease: Appraisal of disease activity. Invest Radiol 2000, 35(7): 431-7. (Pubitemid 30448171)
13. Gomes, P., du Boulay, C., Smith, C. et al. Relationship between disease activity indices and colonoscopic findings in patients with colonic inflammatory bowel disease. Gut 1986, 27(1): 92-5. (Pubitemid 16134482)
14. Solem, C.A., Loftus, E.V., Tremaine, W.J. et al. Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis 2005, 11(8): 707-12. (Pubitemid 41271173)
15. Saverymuttu, S.H., Hodgson, H.J., Chadwick, V.S. et al. Differing acute phase responses in Crohn's disease and ulcerative colitis. Gut 1986, 27(7): 809-13. (Pubitemid 16058500)
16. Koelewijn, C.L., Schwartz, M.P., Samsom, M., Oldenburg, B. C-reactive protein levels during a relapse of Crohn's disease are associated with the clinical course of the disease. World J Gastroenterol 2008, 14(1): 85-9. (Pubitemid 351314332)
17. Lichtenstein, G.R., Rutgeerts, P. Importance of mucosal healing in ulcerative colitis. Inflamm Bowel Dis 2010, 16(2): 338-46.
18. Pineton de Chambrun, G., Peyrin-Biroulet, L., Lémann, M., Colombel, J.F. Clinical implications of mucosal healing for the management of IBD. Nat Rev Gastroenterol Hepatol 2010, 7(1): 15-29.
19. Poullis, A., Foster, R., Northfield, T.C. et al. Review article: faecal markers in the assessment of activity in inflammatory bowel disease. Aliment Pharmacol Ther 2002, 16(4): 675- 81.
20. Langhorst, J., Elsenbruch, S., Mueller, T. et al. Comparison of 4 neutrophil-derived proteins in feces as indicators of disease activity in ulcerative colitis. Inflamm Bowel Dis 2005, 11(12): 1085-91. (Pubitemid 41682565)
21. Lundberg, J.O., Hellstrom, P.M., Fagerhol, M.K. et al. Technology insight: calprotectin, lactoferrin and nitric oxide as novel markers of inflammatory bowel disease. Nat Clin Pract Gastroenterol Hepatol 2005, 2(2): 96-102. (Pubitemid 40790156)
22. Schoepfer, A.M., Trummler, M., Seeholzer, P. et al. Accuracy of four fecal assays in the diagnosis of colitis. Dis Colon Rectum 2007, 50(10): 1697-706. (Pubitemid 47583348)
23. D'Inca, R., Pont, E., Leo, V. et al. Calprotectin and lactoferrin in the assessment of intestinal inflammation and organic disease. Int J Colorectal Dis 2007, 22(4): 429-37. (Pubitemid 46336248)
24. Angriman, I., Scarpa, M., D'Inca, R. et al. Enzymes in feces: useful markers of chronic inflammatory bowel disease. Clin Chim Acta 2007, 381(1): 63-8. (Pubitemid 46719135)
25. Sipponen, T., Savilahti, E., Kolho, K., Nuutinen, H., Turunen, U., Farkkila, M. Crohn's disease activity assessed by calprotectin and lactoferrin: Correlation with Crohn's disease activity index and endoscopic findings. Inflamm Bowel Dis 2008, 14(1): 40-6. (Pubitemid 351196867)
26. Schoepfer, A.M., Trummler, M., Seeholzer, P. et al. Discriminating IBD from IBS: comparison of the test performance of fecal markers, blood leukocytes, CRP, and IBD antibodies. Inflamm Bowel Dis 2008, 14(1): 32-9. (Pubitemid 351196866)
27. Sutherland, A.D., Gearry, R.B., Frizelle, F.A. Review of fecal biomarkers in inflammatory bowel disease. Dis Colon Rectum 2008, 51(8): 1283-91.
28. Gisbert, J.P., McNicholl, A.G., Gomollon, F. Questions and answers on the role of fecal lactoferrin as a biological marker in inflammatory bowel disease. Inflamm Bowel Dis 2009, 15(11): 1746-54.
29. Schroeder, O., Naumann, M., Shastri, Y. et al. Prospective evaluation of faecal neutrophil-derived proteins in identifying intestinal inflammation: combination of parameters does not improve diagnostic accuracy of calprotectin. Aliment Pharmacol Ther 2007, 26(7): 1035-42. (Pubitemid 47416301)
30. Otten, C.M., Kok, L., Witteman, B.J. et al. Diagnostic performance of rapid tests for detection of fecal calprotectin and lactoferrin and their ability to discriminate inflammatory from irritable bowel syndrome. Clin Chem Lab Med 2008, 46(2): 1275-80.
31. Shastri, Y., Povse, N., Stein, J.A. Prospective comparative study for new rapid bedside fecal calprotectin test with an established ELISA to assess intestinal inflammation. Clin Lab 2009, 55(1-2): 53-5.
32. Masson, P., Heremans, J., Schonne, E. Lactoferrin, an ironbinding protein in neutrophilic leukocytes. J Exp Med 1969, 130(3): 643-58.
33. Mason, D., Taylor, C. Distribution of transferrin, ferritin, and lactoferrin in human tissue. J Clin Path 1978, 31(4): 316-27. (Pubitemid 8315980)
34. Masson, P., Heremans, J. Lactoferrin in milk from different species. Comp Biochem Physiol B 1971, 39(1): 119-29.
35. Wong, S., Francis, N., Chahal, H., Raza, K., Salmon, M., Scheel-Toellner, D., Lord, J. Lactoferrin is a survival factor for neutrophils in rheumatoid synovial fluid. Rheumatology 2009, 48(1): 39-44.
36. Francis, N., Wong, S., Hampson, P. et al. Lactoferrin inhibits neutrophil apoptosis via blockade of proximal apoptotic signaling events. Biochim Biophys Acta 2011, 1813(10): 1822-6.
37. Fine, K.D., Ogunji, F., George, J. et al. Utility of a rapid fecal latex agglutination test detecting the neutrophil protein, lactoferrin, for diagnosing inflammatory causes of chronic diarrhea. Am J Gastroenterol 1998, 93(8): 1300-5. (Pubitemid 29076931)
38. Dai, J., Liu, W.Z., Zhao, Y.P., Hu, Y.B., Ge, Z.Z. Relationship between fecal lactoferrin and inflammatory bowel disease. Scand J Gastroenterol 2007, 42(12): 1440-4. (Pubitemid 350125546)
39. Hirata, I., Hoshimoto, M., Saito, O. et al. Usefulness of fecal lactoferrin and hemoglobin in diagnosis of colorectal diseases. World J Gastroenterol 2007, 13(10): 1569-74. (Pubitemid 46672666)
40. Guerrant, R., Araujo, V., Soares, E., Kotloff, K., Lima, A., Cooper, W., Lee, A. Measurement of fecal lactoferrin as a marker of fecal leukocyte. J Clin Microbiol 1992, 30(5): 1238-42.
41. Uchida, K., Matsuse, R., Tomita, S., Sugi, K., Saitoh, O., Ohshiba, S. Immunochemical detection of human lactoferrin in feces as a new marker for inflammatory gastrointestinal disorders and colon cancer. Clin Biochem 1994, 27(4): 259-64. (Pubitemid 24300418)
42. Sugi, K., Saitoh, O., Hirata, I., Katsu, K. Fecal lactoferrin as a marker for disease activity in inflammatory bowel disease: Comparison with other neutrophil-derived proteins. Am J Gastroenterol 1996, 91(5): 927-34. (Pubitemid 26143531)
43. Tibble, J.A., Bjarnason, I. Non-invasive investigation of inflammatory bowel disease. World J Gastroenterol 2001, 7(4): 460-5. (Pubitemid 32782620)
44. Sidhu, R., Wilson, P., Foye, L., McAlindon, M., Lobo, A., Morley, S., Sanders, D. Can fecal lactoferrin be used as a discriminator for referral for colonoscopy? Intern Med J 2010, 40(12): 867-8.
45. Dwarakanath, A.D., Finnie, I.A., Beesley, C.M. et al. Differential excretion of leucocyte granule components in inflammatory bowel disease: Implications for pathogenesis. Clin Science 1997, 92(3): 307-13. (Pubitemid 27129445)
46. Kane, S., Sandborn, W.J., Rufo, P.A. et al. Fecal lactoferrin is a sensitive and specific marker in indentifying intestinal inflammation. Am J Gastroenterol 2003, 98(6): 1309-14. (Pubitemid 36741528)
47. Kayazawa, M., Saitoh, O., Kojima, K. et al. Lactoferrin in whole gut lavage fluid as a marker for disease activity in inflammatory bowel disease: Comparison with other Neutrophil-Derived proteins. Am J Gastroenterol 2002, 97(2): 360-9. (Pubitemid 34160762)
48. Jones, J., Loftus, E., Panaccione, R. et al. Relationship between disease activity and serum and fecal biomarkers in patients with Crohn's disease. Clin Gastroenterol Hepatol 2008, 6(11): 1218-24.
49. Sipponen, T., Karkkainen, P., Savilahti, E. et al. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological findings. Aliment Pharmacol Ther 2008, 28(10): 1221-9.
50. Sidhu, R., Sanders, D., Wilson, P., Foye, L., Morley, S., McAlindon, M. Faecal lactoferrin, capsule endoscopy and Crohn's disease. Is there a three way relationship? A pilot study. J Gastointestin Liver Dis 2010, 19(3): 257-60.
51. Parsi, M., Shen, B., Achkar, J. et al. Fecal lactoferrin for diagnosis of symptomatic patients with ileal pouch-anal anastomosis. Gastroenterology 2004, 126(5): 1280-6. (Pubitemid 38552792)
52. Scarpa, M., Grillo, A., Faggian, D. et al. Relationship between mucosa-associated microbiota and inflammatory parameters in the ileal pouch after restorative proctocolectomy for ulcerative colitis. Surgery 2011, 150(1): 56-67.
53. Joishy, M., Davies, I., Ahmed, M., Wassel, J., Davies, K., Sayers, A., Jenkins, H. Fecal calprotectin and lactoferrin as noninvasive markers of pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2008, 48(1): 48-54.
54. Walker, T., Land, M., Kartashov, A., Saslowsky, T., Lyerly, D., Boone, J., Rufo, R. Fecal lactoferrin is a sensitive and specific marker of disease activity in children and young adults with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007, 44(4): 414-22. (Pubitemid 46573222)
55. Pfefferkorn, M., Boone, J., Nguyen, J., Juliar, B., Davis, M., Parker, K. Utility of fecal lactoferrin in identifying Crohn's disease activity in children. J Pediatr Gastroenterol Nutr 2010, 51(4): 425-8.
56. Joshi, S., Lewis, S., Creanor, S., Ayling, R. Age-related faecal calprotectin, lactoferrin, and tumour M2-PK concentrations in healthy volunteers. Ann Clin Biochem 2010, 47(Pt. 3): 259-63.
57. Buderus, S., Boone, J., Lyerly, D., Lentze, M. Fecal lactoferrin: A new parameter to monitor infliximab therapy. Dig Dis Sci 2004, 49(6): 1036-9. (Pubitemid 39012291)
58. Sipponen, T., Savilahti, E., Karkkainen, P. et al. Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-TNF-alpha therapy for Crohn's disease. Inflamm Bowel Dis 2008, 14(10): 1392-8.
59. Sipponen, T., Björkesten, C.G., Färkkilä, M., Nuutinen, H., Savilahti, E., Kolho, K.L. Faecal calprotectin and lactoferrin are reliable surrogate markers of endoscopic response during Crohn's disease treatment. Scand J Gastroenterol 2010, 45(3): 325-31.
60. Ruffolo, C., Scarpa, M., Faggian, D. et al. Subclinical intestinal inflammation in patients with Crohn's disease following bowel resection: A smoldering fire. J Gastrointest Surg 2010, 14(1): 24-31.
61. Lamb, C., Mohiuddin, M., Gicquel, J., Neely, D., Bergin, F., Hanson, J., Mansfield, J. Faecal calprotectin or lactoferrin can identify postoperative recurrence in Crohn's disease. Br J Surg 2009, 96(6): 663-74.
62. Opintan, J.A., Newman, M.J., Ayeh-Kumi, P.F. et al. Pediatric diarrhea in southern Ghana: etiology and association with intestinal inflammation and malnutrition. Am J Trop Med Hyg 2010, 83(4): 936-43.